Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + Paclitaxel + Ramucirumab in Advanced Gastro-esophageal Adenocarcinoma
NCT03966118Phase 2Unknown
- Start
- Apr 2019
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in gastroesophageal adenocarcinoma. Primary endpoint: Overall Survival Rate at 6 months. Status: unknown.
02
Drugs
avelumab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT03966118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03966118.